Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Mark Mirochnick, MD, M.D

Boston University

Intervention

Bictegravir (BIC)(drug)

Enrollment

205 enrolled

Eligibility

FEMALE

Timeline

2021 – 2025

Study locations (23)

• Usc La Nichd Crs, Los Angeles, California, United States
• David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States
• University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, San Diego, California, United States
• Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
• South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States
• University of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
• Pediatric Perinatal HIV NICHD CRS, Miami, Florida, United States
• Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
• Rush University Cook County Hospital Chicago NICHD CRS, Chicago, Illinois, United States
• Lurie Children's Hospital of Chicago (LCH) CRS (Site ID: 4001), Chicago, Illinois, United States
• Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States
• Bronx-Lebanon Hospital Center NICHD CRS, The Bronx, New York, United States
• Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx, New York, United States
• Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil
• Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil
• +8 more locations on ClinicalTrials.gov

Collaborators

International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Institute of Mental Health (NIMH) · Gilead Sciences · ViiV Healthcare · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →